

# The 3rd International Symposium of Clinical Immunology

## Program

Thursday 16 May 2024

### Opening Address

15:20-15:30

Tatsuya Atsumi (President of the 3rd International Symposium of Clinical Immunology)

### Educational Lecture 1

15:30-16:20

Sponsored by CSL Behring K.K.

Chair Tomohiro Morio (Tokyo Medical and Dental University (TMDU), Tokyo, Japan)

EL-1 Contemporary Evaluation and Treatment of Primary Antibody Deficiency in Adults

Antoine Azar (Interim Division Director, Allergy and Clinical Immunology / Clinical Director, Division of Allergy and Clinical Immunology / Director, Adult Primary Immunodeficiency Center, Johns Hopkins School of Medicine, Baltimore, MD)

### Oral Session

16:20-17:10

Chairs Sachiko Miyake (Department of Immunology, Juntendo University Graduate School of Medicine, Tokyo, Japan)

Hiroshi Nakajima (Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan)

O-1 Identification of a novel age-associated CD4<sup>+</sup> T cell subset that exhibits both cytotoxic phenotype and B cell helper function involved in the pathogenesis of systemic lupus erythematosus

Manaka Goto (Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan)

O-2 The role of RasGRP1 in idiopathic inflammatory myopathies

Marina Kise (Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan)

O-3 Immunoglobulin-like transcript 2 as an impaired anti-tumor cytotoxicity marker of natural killer cells in patients with hepatocellular carcinoma

Sachiyo Yoshio (Department of Liver Diseases, National Center for Global Health and Medicine, Chiba, Japan)

O-4 Clinical significance of follicular helper T (Tfh) cell subsets in systemic lupus erythematosus (SLE)

Yurie S. Kanda (The first department of Internal Medicine, University of Occupational and Environmental Health, Japan, School of Medicine, Kitakyusyu, Japan)

O-5 Serum C-type lectin domain family 7 member A reflects disease activity in patients with systemic lupus erythematosus

Yuki Kudo (Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan)

## Evening Seminar 1

17:20-18:10

Sponsored by Otsuka Pharmaceutical Co., Ltd. Medical Affairs

Chair Yoshiya Tanaka (The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan)

ES-1 The pathogenesis of systemic lupus erythematosus; focus on T cells

Michihito Kono (Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Hokkaido, Japan)

**Friday 17 May 2024**

**Morning Seminar 1**

8:00-8:50

Sponsored by AstraZeneca K.K.

Chair Kunihiro Yamaoka (Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan)

**MS-1 Role for Anifrolumab in SLE treatment ~ what will change after EULAR recommendations2023 update? ~**

Shingo Nakayamada (The First Department of Internal Medicine, University of Occupational & Environmental Health, Japan, Kitakyushu Fukuoka, Japan)

**Symposium 1**

9:00-10:40

**Organ-specific immunological disease**

Chairs Hiroshi Nakase (Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan)

Yoshihide Asano (Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan)

**S1-1 Recent advance in Inflammatory bowel disease**

Tadakazu Hisamatsu (Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Tokyo, Japan)

**S1-2 Advances in Understanding the Pathophysiology of IgG4-Related Dacryoadenitis and Sialadenitis: A Comprehensive Review**

Motohisa Yamamoto (Department of Rheumatology and Allergy, IMSUT Hospital, Tokyo, Japan)

**S1-3 Evolving Treatment strategy in Neuroimmunological Diseases**

Noriko Isobe (Department of Neurology, Kyushu University, Fukuoka, Japan)

**S1-4 Psoriatic lesion formation and local immune memory**

Rei Watanabe (Department of Dermatology, Juntendo University, Tokyo, Japan)

Sponsored by Eli Lilly Japan K.K.

Chair Tatsuya Atsumi (Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan)

**LS-1 Baricitinib – What have we learned from clinical trials and real world evidence**

Christopher Edwards (NIHR Southampton Clinical Research Facility, University Hospital Southampton, UK & University of Southampton, UK)

**Symposium 2**

12:10-14:10

**Pathophysiology and mechanism of ICB-induced immune-related adverse events**

Chairs Toshihiko Torigoe (Department of Pathology 1, Sapporo Medical University School of Medicine, Sapporo, Japan)

Kosaku Murakami (Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan)

**S2-1 Tumor-mediated Education of Bone Marrow Neutrophil Progenitors Facilitates the Development of Checkpoint Inhibitor-associated Toxicity**

Brent A. Hanks (Departments of Medicine, Pharmacology and Cancer Biology, Duke University, Durham, USA)

**S2-2 Lesson from aged mouse model for understanding irAE pathogenesis associated with cancer immunotherapy**

Hirotake Tsukamoto (Division of Clinical Immunology and Cancer Immunotherapy, Center for Cancer Immunotherapy and Immunobiology, Kyoto University, Kyoto, Japan)

**S2-3 Clinical and immunological features of irAE myositis**

Shigeaki Suzuki (Department of Neurology, Keio University School of Medicine, Tokyo, Japan)

**S2-4 Mechanisms of immune-related adverse events in endocrine organs**

Shintaro Iwama (Department of Endocrinology and Diabetes, Nagoya University Hospital, Nagoya, Japan)

**S2-5 Exploring Genetic Factors Predisposing to through a Genome-Wide Association Study: Are there genetic factors associated with irAEs?**

Hideaki Miyamoto (Department of Gastroenterology and Hepatology, Kumamoto University Hospital, Kumamoto, Japan)

## Educational Lecture 2

14:40-15:30

Sponsored by Sanofi K.K.

Chair Hiroaki Niiro (Department of Medical Education, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan)

### EL-2 Pathophysiology and management of acquired TTP

Masanori Matsumoto (Department of Hematology and Blood Transfusion Medicine, Nara Medical University, Nara, Japan)

## Educational Lecture 3

15:30-16:20

Sponsored by GlaxoSmithKline K.K.

Chair Naoto Tamura (Department of Internal Medicine and Rheumatology, Juntendo University Faculty of Medicine, Tokyo, Japan)

### EL-3 Importance of long-term organ damage control in SLE ~updated recommendations and guidelines~

Munther Khamashta (GlaxoSmithKline K.K., Dubai Health Care City, United Arab Emirates)

## Evening Seminar 2

16:30-17:20

Sponsored by Gilead Sciences K.K. / Eisai Co., Ltd.

Chair Isao Matsumoto (Department of Rheumatology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan)

### ES-2 Immunological basis for the effectiveness and safety of JAK inhibitors in the treatment of rheumatoid arthritis

Keishi Fujio (Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan)

## Poster Presentation

17:30-18:10

### P-1 JAK-STAT signaling and GM-CSF promote the development of osteitis and bone microstructure changes in rheumatoid arthritis

Tsuneyasu Yoshida (Department of Rheumatology and Clinical Immunology, Kyoto University, Graduate School of Medicine, Kyoto, Japan)

### P-2 Butyric acid suppresses migration of monocyte derived Dendritic Cell by inhibiting Actin polymerization via mDia1 inhibition

Takumi Nagamoto (Department of Endocrinology and Rheumatology, Kurashiki Central Hospital, Kurashiki, Japan)

### P-3 Lnk/Sh2b3 suppresses the pathogenesis of MAFLD through the regulation of IL-15 signalling in CD8<sup>+</sup> T cells

Taizo Mori (Department of liver disease, National center of global and medicine, Chiba, Japan)

P-4 Canceled

P-5 A-to-I RNA editing is implicated in cancer cell–immune cell crosstalk associated with survival for glioblastoma patients  
Sean chun-chang Chen (Graduate Institute of Biomedical Informatics, Taipei Meidcal University, Taipei, Taiwan)

P-6 Deficiency of serum short-chain fatty acids is associated with enhancement of plasmocyte differentiation in systemic lupus erythematosus  
Ryuichiro Kanda (First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Fukuoka, Kitakyusyu, Japan)

P-7 Role of IFNg producing CD4+T cells in imiquimod-induced SLE model mice  
Reona Tanimura (Department of Rheumatology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan)

P-8 Semaphorin 6D maintains amygdalar neural integrity to coordinate emotional, metabolic and inflammatory outputs  
Mayuko Izumi (Department of Respiratory Medicine and Clinical Immunology, Graduate School of medicine, Osaka University, Osaka, Japan)

P-9 Castleman disease (iMCD-NOS) maybe a Tph cell infiltrated immunological disorder  
Kazuyuki Yoshizaki (Osaka University, Osaka, Japan)

P-10 Epidermal cells and alveolar epithelial cells play a crucial role in recruiting monocytes/macrophages via the CX3CL1/CX3CR axis in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis  
Yasuhiro Nohda (Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan)

P-11 Single-cell RNA sequencing of peripheral blood mononuclear cells reveals immune cell signatures in Japanese patients with autoimmune hepatitis  
Kazumichi Abe (Department of Gastroenterology, Fukushima Medical University, Fukushima, Japan)

P-12 Impact of diet therapy on gut microbiome composition and immunological status in patients with phenylketonuria  
Natsuki Ohmi (Department of Pediatrics and Child Health, Nihon University School of Medicine, Tokyo, Japan)

P-13 Pathogenic role of inflammasome activation and interleukin-1 $\beta$  overproduction in Kawasaki disease  
Shuya Kaneko (Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan)

P-14 Identification of Semaphorin 3E as a novel target for the treatment of neuropathic pain  
Sato Yoshidomi (Department of Neurology, Kyushu University, Fukuoka, Japan)

P-15 Steroid-resistant Vogt-Koyanagi-Harada-like uveitis due to BRAF/MEK inhibitor successfully treated with adalimumab  
Manami Watanabe (Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan)

P-16 Plasma amino acid concentration suggests skeletal muscle catabolism in patients with IgG4-related disease  
Hiroyuki Nakamura (Department of Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan)

P-17 Double filtration plasmapheresis reduces type I interferon bioavailability and inducing activity in plasma from patients with systemic lupus erythematosus  
Takumi Saito (Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan)

P-18 The maintenance dose of glucocorticoid in the management of systemic lupus erythematosus  
Chihiro Imaizumi (Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Tokyo, Japan)

P-19 Distinguishing Clinical and Serological Features of Immune-related Adverse Events-related Arthritis (irAE-A) and Rheumatoid Arthritis (RA): Serum Globulin as a Potential Predictor of RA Relapse After Immune Checkpoint Inhibitor Therapy  
Shion Kachi (Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan)

P-20 A case of acquired pure red cell aplasia associated with rheumatoid arthritis successfully treated with rituximab  
Yuya Wada (Department of Gastroenterology, Obihiro Kosei Hospital, Obihiro, Japan)

P-21 Prediction of the low disease activity and remission after 1-year of treatment with Belimumab in Patients with Systemic Lupus Erythematosus  
Yasuhiro Hasegawa (Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan)

P-22 The efficacy and safety of the recombinant zoster vaccine in rheumatoid arthritis patients treated with JAK inhibitors: A single-center, retrospective analysis in Japan  
Moemi Yabe (Department of Rheumatology, Kitaharima Medical Center, Ono, Japan)

P-23 Novel therapy; A combination therapy of dupilumab and topical immunotherapy for severe alopecia areata associated atopic dermatitis  
Toshiaki Kogame (Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan)

P-24 The role of the complement alternative pathway in Immune Thrombocytopenia  
Risa Shindo (Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan)

P-25 Rapid efficacy of ravulizumab at the stage of early fast-acting treatment in one patient suffered with ventilator-dependent myasthenic crisis  
Chenyao Wang (Department of neurology, Tenri hospital, Tenri, Nara, Japan)

P-26 The triple combination of baricitinib, rituximab, and tacrolimus therapy (BRT-Tx.) for anti-MDA5 antibody-positive dermatomyositis (MDA5-DM) was revealed to be superior to conventional tacrolimus and cyclophosphamide therapy (TC-Tx) by transcriptome analysis of peripheral blood  
Yu Nakai (Collagen Disease and Rheumatology, Japanese Red Cross Okayama Hospital, Okayama, Japan)

P-27 A case of chronic recurrent multifocal osteomyelitis associated with a *NLRP12* gene mutation  
Koki Nakamura (Department of Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan)

**Saturday 18 May 2024**

**Morning Seminar 2**

8:00-8:50

Sponsored by Mitsubishi Tanabe Pharma Corporation

Chair **Takao Fujii** (Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Japan)

**MS-2 TNF $\alpha$  as a primary target of treatment for rheumatoid arthritis**

**Shinsuke Yasuda** (Department of Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan)

**Symposium 3**

9:00-10:40

**Pathology and clinical status of systemic autoimmune diseases**

Chairs **Tatsuya Atsumi** (Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan)

**Isao Matsumoto** (Department of Rheumatology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan)

**S3-1 B cell biology of SLE in the light of B cell receptor repertoire abnormality**

**Mineto Ota** (Department of Genetics, Stanford University, CA, United States)

**S3-2 Pathogenesis of PBC and latest clinical findings**

**Nobuhiro Nakamoto** (Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan)

**S3-3 The dynamic cell-cell interactions at inflamed salivary glands in primary Sjögren syndrome**

**Hiromitsu Asashima** (Department of Rheumatology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan)

**S3-4 The involvement of neutrophil extracellular traps in the pathogenesis of ANCA-associated vasculitis**

**Daigo Nakazawa** (Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan)

## Luncheon Seminar 2

11:10-12:00

Sponsored by AbbVie GK

Chair Tatsuya Atsumi (Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan)

**LS-2 Efficacy/effectiveness and safety of upadacitinib in immune-mediated inflammatory diseases**

Hideto Kameda (Division of Rheumatology, Department of Internal Medicine, Toho University, Tokyo, Japan)

## Closing Address

12:00-12:10

Tatsuya Atsumi (President of the 3rd International Symposium of Clinical Immunology)

Sachiko Miyake (President of the 52nd Annual Meeting of the Japanese Society of Clinical Immunology)

Hideto Kameda (President of the 4th International Symposium of Clinical Immunology)